GSK vs PBYI · P/E 13, $103.31B cap vs P/E 4.3, rev $56.5M
GlaxoSmithKline PLC ADR (GSK) versus Puma Biotechnology Inc (PBYI) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
GSK does not have a complete income-statement cache yet.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Not investment advice. Open the GSK and PBYI stock pages for the full models.
Not investment advice.